Keros Therapeutics Inc KROS

$10.05 -0.03 (-0.30%)

Valuation

Market cap
187,213,000
Revenue TTM
$244,060,000
Net income TTM
$87,010,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
35.65%
Debt to equity
0.00

Trading

Volume
43,918
Avg volume
186,138
Day's range
$9.55 – $10.17
Shares out
19,624,000
Stochastic %K
46%
Beta
1.13
Analysts
Moderate Buy
Price target
$18.86

Price

Company profile

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne...

Show more

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 314 6297
Website
https://www.kerostx.com
Address
1050 Waltham Street, Suite 302, Lexington, United States

Latest news

Stocktwits

buyandsold Nov 12, 4:54 AM
$KROS poor DMD patients duped into a greenmailers scheme to generate RSUs and fat salaries.
1 replies
Valueforall Oct 28, 5:04 PM
$RGNX same goes for this ticker $KROS
0 replies
focafoca99 Sep 28, 12:18 PM
$KROS announces first patient dosed in Phase 2 trial of rinvatercept for Duchenne muscular dystrophy.
0 replies
Valueforall Sep 22, 6:57 PM
$KROS there are gonna be quite a few boners& around the market especially low float bios like this one
0 replies
Valueforall Sep 22, 2:58 PM
$KROS buy this dip! Buy this rip! So cheap! Insiders bought at $17+. They giving away at 11$ during the data 🌵
0 replies
amessagefromtheodd Sep 20, 12:11 AM
$CADL $IOVA $KROS $SLS $VXRT Count down October.
1 replies
Valueforall Sep 9, 1:46 PM
$KROS I buy the rips and I buy the dips. I also buyy the lulls
0 replies
Valueforall Sep 2, 1:39 PM
$KROS I keep buying despite the color. Why?
0 replies